18+ · Research use only
Tirzepatide · Phase 3 · Completed
SURMOUNT-2
In SURMOUNT-2, a phase 3 trial of tirzepatide in adults (18 or older) with BMI of 27 kg/m2 or higher and type 2 diabetes with HbA1c 7-10% (53-86 mmol/mol), in seven countries (n=938), mean body weight fell 12.8% on 10 mg and 14.7% on 15 mg over 72 weeks, against 3.2% on placebo (treatment-regimen estimand; Garvey WT et al. Lancet 2023 (SURMOUNT-2)).
Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked.
Updated 24 September 2026
Results
Side effects reported
SURMOUNT-2: The abstract reports that few adverse events led to discontinuation (under 5%) without per-arm figures.
Design
Trial design and sources
- Compound
- Tirzepatide
- Phase
- 3
- Population
- Adults (18 or older) with BMI of 27 kg/m2 or higher and type 2 diabetes with HbA1c 7-10% (53-86 mmol/mol), in seven countries
- Participants randomised
- 938
- Duration
- 72 weeks
- Primary endpoint
- Coprimary: percent change in bodyweight from baseline and bodyweight reduction of 5% or higher (week 72)
- Estimand
- treatment-regimen
- Read out
- 26 June 2023
The abstract reports that few adverse events led to discontinuation (under 5%) without per-arm figures.
Questions
SURMOUNT-2, answered
What did SURMOUNT-2 find?
In SURMOUNT-2, a phase 3 trial of tirzepatide in adults (18 or older) with BMI of 27 kg/m2 or higher and type 2 diabetes with HbA1c 7-10% (53-86 mmol/mol), in seven countries (n=938), mean body weight fell 12.8% on 10 mg and 14.7% on 15 mg over 72 weeks, against 3.2% on placebo (treatment-regimen estimand; Garvey WT et al. Lancet 2023 (SURMOUNT-2)).
What side effects were reported in SURMOUNT-2?
SURMOUNT-2: The abstract reports that few adverse events led to discontinuation (under 5%) without per-arm figures.
Related